IA tenecteplaseintra-arterial (IA) tenecteplasestandard medical management
…n in ICA patients (51.5%) versus MCA M1 (37.9%) and M2 (25.7%). IA tenecteplase had a lower any intracranial hemorrhage within 48 hours in ICA …
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 421–480 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
OCA8Daratumumab8TCE8Sunitinib8memantine8Calprotectin8Ribociclib8Dobutamine8sulfonylurea8Entinostat8Imatinib8Encorafenib8Rifapentine8SLEDAI8Canagliflozin8Dopamine8Maralixibat8Retatrutide8Bisoprolol8Daptomycin8Etanercept8DOAC8Parecoxib8Progesterone8chloroquine8Botulinum toxin8Quetiapine8Trastuzumab deruxtecan8high-intensity statin8local anaesthetic8Magnesium8mifepristone8GLP-18Albendazole8Hypertonic saline8PBS8Valproic acid8macrolides8Interleukin-68Mounjaro8Tylenol8Ursodeoxycholic acid (UDCA)8haloperidol8tenofovir alafenamide8NIVO7Bedaquiline7Glyburide7Nerandomilast7αPD-17Axi-Cel7Terlipressin7Butyrate75-ASA7IQOS7Ofatumumab7tPA7SGLT-2 Inhibitors7BsAb7Cladribine7Curcumin7
Articles mentioning drugs
10,506 articles · page 177 of 876DMTbreast cancermultiple sclerosisChemotherapy
…irmed disability progression (CDP) after cancer diagnosis, with DMT modelled as a time-varying covariate. Propensity score matching…
trastuzumabzoledronic acidlapatinibabirateroneoxaliplatinCancer drugsimmunotherapeutic agentsrenal cell carcinomabreast cancercolon cancer+5 more
…vant therapy for oxaliplatin in colon cancer or the duration of trastuzumab in breast cancer, FDA labels are not regularly updated,25 and t…
CM313persistent or chronic primary immune thrombocytopeniapersistent or chronic immune thrombocytopeniaglucocorticoid treatment
…elated reactions and petechiae being the most common.Conclusion CM313 showed a favourable safety profile and encouraging efficacy in …
dextroamphetamineamphetaminemethamphetaminecardiovascular complicationspsychiatric comorbiditiesinjection-related infectionsEuropean Medicines AgencyATLAS4Dependenceopioid agonist treatmentpoor social functioning+1 more
…t. Participants will be randomly assigned 1:1 to receive either dextroamphetamine or placebo for 12 weeks. Flexible doses within the range of 30–…
Onyx 18diluted OnyxOnyxcSDHchronic subdural hematomas (cSDH)our institution
…lizations performed at our institution, 99 were performed using Onyx 18 only. Within this cohort, 53 (53.5%) cases used standard Onyx a…
LorundrostatOsilodrostatBaxdrostatResistant hypertensionhypertension
…emonstrated the most consistent efficacy across outcomes, while Lorundrostat also showed potential benefit. This analysis supports the use o…
aldosteronereninaldosterone-reninessential hypertensionEmbasehypertensionMEDLINEFramingham study
…comes are to assess if there are ethnic differences in baseline aldosterone, baseline plasma renin activity (PRA) and ARR. We will also loo…
natalizumabMSrelapsing-remitting multiple sclerosisprogressive multifocal leukoencephalopathy
…ower compared with those with high trough concentrations during natalizumab treatment. This emphasises the importance of personalised EID, …
MavacamtenSix-Minute Walk TestNICEBelfast Inherited Cardiac Services CentreoHCMsymptomatic obstructive hypertrophic cardiomyopathy
…Introduction Mavacamten, a first-in-class cardiac myosin inhibitor, received NICE appro…
BNPheart failure
…C transitions (83.0 to 220.0 pg/mL) (table 2)Conclusions Serial BNP and echocardiographic monitoring reveal progressive and regress…
lidocaineAdenosineAdenosine-Lidocaine-Magnesiummagnesiumhaemorrhagic shockischemic metabolic insufficiencytraumatic-haemorrhagic shock
…n HL, Granfeldt A, Jensen TH, Mattson TH, Dobson GP. Adenosine, lidocaine, and magnesium support a high flow, hypotensive, vasodilatory s…